Key result
Intracoronary bradykinin cuts reperfusion noradrenaline release ~86% and reduces sustained VT in dogs.
Why the study?
The effects of intracoronary bradykinin infusion on noradrenaline release and ventricular arrhythmias following coronary occlusion and reperfusion were investigated.
Does intracoronary bradykinin infusion reduce noradrenaline release and ventricular arrhythmias following reperfusion of ischemic myocardium in anesthetized dogs?
Population
14 anesthetized adult mongrel dogs undergoing 60 min LAD occlusion and 30 min reperfusion
Comparison
Intracoronary bradykinin infusion vs vehicle (Lactate Ringer) infusion
Design
Preclinical experimental study
Follow-up
30 min reperfusion period
Authors
Loading...
Hypothesis-generating for bradykinin in reperfusion; leaves open translation to human practice.
Does intracoronary bradykinin infusion reduce noradrenaline release and ventricular arrhythmias following reperfusion of ischemic myocardium in anesthetized dogs?
Absolute Event Rate: 11.9% vs 82.1%
Intracoronary bradykinin reduces cardiac noradrenaline release and protects against reperfusion-induced sustained ventricular tachycardia in a canine model of ischemia-reperfusion.
Ribuot et al. (1994) studied Ischemia-reperfusion injury (n=14). Intracoronary bradykinin vs. Lactate Ringer vehicle was evaluated on Amount of noradrenaline released at reperfusion. Intracoronary bradykinin infusion significantly reduced noradrenaline release at reperfusion (11.9 vs 82.1 ng/min) and the incidence of sustained ventricular tachycardia in dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: